Mayo Clinic Laboratories > Neurology > Autoimmune > Necrotizing autoimmune myopathy

Necrotizing autoimmune myopathy

A targeted and accelerated approach to diagnosis

Immune-mediated necrotizing myopathy (IMNM), also called necrotizing autoimmune myopathy (NAM), is a rare but serious muscle disease strongly associated with autoantibodies to either signal recognition protein (SRP-IgG) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR-IgG). Our testing can provide earlier identification and treatment initiation in patients with IMNM, which is critical to preventing further harm.

Necrotizing autoimmune myopathy Test menu

Necrotizing autoimmune myopathy

Key testing

Advantages

  • A single evaluation with the two most pertinent antibodies associated with IMNM: HMGCR-IgG and SRP-IgG. The combination of both antibodies maximizes clinical sensitivity for diagnosing patients with this disease.
  • Detection of SRP-IgG using a sensitive immunofluorescence-based assay and then confirming by a second immunoblot technology.
  • Antibodies are tested in parallel, providing results in approximately one week.

Highlights

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.